Find the products and resources you are looking for!
Get in touch!
Our local employees are always happy to answer your questions. Highly trained and experienced teams in your country can provide quick, helpful, and comprehensive support.
Miltenyi Biotec distribution:
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Cookie Settings
We use cookies in order to provide the best possible website experience for you. This includes cookies that are technically required to ensure a proper functioning of the website, as well as cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for displaying personalized content. You are free to choose the categories you would like to permit. Please note that depending on your settings, the full functionality of the website may no longer be available. Further information can be found in our Privacy Statement.
Recently, impressive progress in treatment of solid tumors could be achieved by use of checkpoint inhibitors. However, still many patients relapse after checkpoint inhibitor therapy and the challenge remains to predict which patient will benefit best from which drug. This question will be addressed in ImmunePredict: We will develop novel tools to predict the optimal treatment strategy for each individual cancer patient.
The research consortium ImmunePredict combines essential cutting-edge technologies to collect and process a multitude of genomic and proteomic information in parallel: a novel imaging platform named “Multidimensional In-Situ Cytometry Survey“ (MICS), together with a comprehensive molecular characterization of tumors and advanced digital image analysis algorithms will be related to the individual patient’s actual response to immune-checkpoint-inhibitor-therapy.
The University of Cologne as coordinator, the University of Applied Sciences Hamm-Lippstadt and Miltenyi Biotec
Funded by the European Regional Development Fund North Rhine Westfalia, LS-2-1-002b
Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.